CN118047872A - 抗cd30l抗体和其用途 - Google Patents

抗cd30l抗体和其用途 Download PDF

Info

Publication number
CN118047872A
CN118047872A CN202410189800.6A CN202410189800A CN118047872A CN 118047872 A CN118047872 A CN 118047872A CN 202410189800 A CN202410189800 A CN 202410189800A CN 118047872 A CN118047872 A CN 118047872A
Authority
CN
China
Prior art keywords
cdr
amino acid
acid sequence
seq
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410189800.6A
Other languages
English (en)
Chinese (zh)
Inventor
杰西-法拉·菲克特奥
马克·伦萧
乔汉·法兰森
奥立维尔·劳伦特
伯顿·巴奈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Falk Pharma GmbH
Prometheus Biosciences Inc
Original Assignee
Dr Falk Pharma GmbH
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma GmbH, Prometheus Biosciences Inc filed Critical Dr Falk Pharma GmbH
Publication of CN118047872A publication Critical patent/CN118047872A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202410189800.6A 2021-02-17 2022-02-16 抗cd30l抗体和其用途 Pending CN118047872A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17
US63/150,373 2021-02-17
CN202280028982.8A CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途
PCT/US2022/016565 WO2022177963A1 (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280028982.8A Division CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Publications (1)

Publication Number Publication Date
CN118047872A true CN118047872A (zh) 2024-05-17

Family

ID=82931610

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410189800.6A Pending CN118047872A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途
CN202280028982.8A Pending CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280028982.8A Pending CN117255802A (zh) 2021-02-17 2022-02-16 抗cd30l抗体和其用途

Country Status (20)

Country Link
US (3) US20240254246A1 (https=)
EP (1) EP4294840A4 (https=)
JP (2) JP7559257B2 (https=)
KR (1) KR20230157356A (https=)
CN (2) CN118047872A (https=)
AR (1) AR124895A1 (https=)
AU (1) AU2022224561A1 (https=)
BR (1) BR112023016445A2 (https=)
CA (1) CA3208060A1 (https=)
CL (1) CL2023002393A1 (https=)
CO (1) CO2023011962A2 (https=)
CR (1) CR20230445A (https=)
EC (1) ECSP23070234A (https=)
GE (3) GEAP202516710A (https=)
IL (1) IL305146A (https=)
JO (1) JOP20230186A1 (https=)
MX (1) MX2023009621A (https=)
PE (1) PE20231680A1 (https=)
TW (1) TW202302637A (https=)
WO (1) WO2022177963A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
AU2023315888A1 (en) * 2022-07-25 2025-02-06 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
AR133766A1 (es) * 2023-09-12 2025-10-29 Amgen Inc Anticuerpos anti-cd30l y usos de los mismos
WO2025075049A1 (ja) * 2023-10-03 2025-04-10 国立大学法人京都大学 ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69334070T2 (de) * 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
SG11201401536QA (en) * 2011-10-21 2014-05-29 Nestec Sa Methods for improving inflammatory bowel disease diagnosis
CN117264057A (zh) * 2012-04-27 2023-12-22 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
EP2945865B1 (en) 2013-01-18 2019-01-09 LORD Corporation Active vibration control devices, systems, and methods
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
EP3405185A4 (en) 2016-01-19 2019-09-18 Thomas Blumenthal BIOMARKERS FOR DOWN SYNDROME AND USES THEREOF
ES2962715T3 (es) * 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof

Also Published As

Publication number Publication date
GEAP202416351A (en) 2024-02-12
GEP20257791B (en) 2025-09-10
CL2023002393A1 (es) 2024-03-22
BR112023016445A2 (pt) 2023-12-12
AR124895A1 (es) 2023-05-17
JP7559257B2 (ja) 2024-10-01
EP4294840A1 (en) 2023-12-27
US20240092923A1 (en) 2024-03-21
GEAP202516710A (en) 2025-05-13
CA3208060A1 (en) 2022-08-25
WO2022177963A1 (en) 2022-08-25
KR20230157356A (ko) 2023-11-16
US20230060624A1 (en) 2023-03-02
TW202302637A (zh) 2023-01-16
US12516126B2 (en) 2026-01-06
JP2025004013A (ja) 2025-01-14
CN117255802A (zh) 2023-12-19
CR20230445A (es) 2023-11-14
CO2023011962A2 (es) 2023-09-29
AU2022224561A1 (en) 2023-09-28
US11866505B2 (en) 2024-01-09
JOP20230186A1 (ar) 2023-08-09
IL305146A (en) 2023-10-01
PE20231680A1 (es) 2023-10-19
ECSP23070234A (es) 2023-10-31
US20240254246A1 (en) 2024-08-01
AU2022224561A9 (en) 2023-10-05
JP2024509746A (ja) 2024-03-05
MX2023009621A (es) 2023-10-31
EP4294840A4 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
JP7559257B2 (ja) 抗ｃｄ３０ｌ抗体およびその使用
AU2020250266B2 (en) Antibodies comprising an ion concentration dependent antigenbinding domain, fc region variants, il-8-binding antibodies, and uses thereof
JP7749549B2 (ja) 抗ｔｓｌｐ抗体及びその使用
KR102844399B1 (ko) 항-cd3-결합 도메인 및 이를 포함하는 항체, 및 이를 생성하고 사용하는 방법
WO2019149269A1 (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
JP7419238B2 (ja) Ｐｄ１結合剤
JP2022540620A (ja) 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤
KR20250057935A (ko) Pdl1 표적화 항체 및 이의 사용 방법
KR20260039798A (ko) ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
TW202513584A (zh) Ｅｎｐｐ３及ｃｄ３結合劑及其使用方法
JP2024509191A (ja) 抗ｖｉｓｔａ構築物およびその使用
RU2807040C2 (ru) Связывающие домены антитела к cd3 и содержащие их антитела, а также способы их получения и применения
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
WO2023001025A1 (zh) Pd-l1抗体及其用途
HK40126939A (zh) 抗vista构建体及其用途
JP2023523760A (ja) 免疫グロブリン変異体
BR122024026051A2 (pt) Anticorpo ou polipeptídeo de ligação a antígeno, seu uso, composição, e artigo de fabricação

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination